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Background: The biologic heterogeneity of soft tissue sarcomas (STS), even within histological subtypes,
complicates treatment. In earlier studies, gene expression patterns that distinguish two subsets of clear cell renal
carcinoma (RCC), serous ovarian carcinoma (OVCA), and aggressive fibromatosis (AF) were used to separate 73 STS
into two or four groups with different probabilities of developing metastatic disease (PrMet). This study was
designed to confirm our earlier observations in a larger independent data set.
Methods: We utilized these gene sets, hierarchical clustering (HC), and Kaplan-Meier analysis, to examine 309 STS,
using Affymetrix chip expression profiling.
Results: HC using the combined AF-, RCC-, and OVCA-gene sets identified subsets of the STS samples. Analysis
revealed differences in PrMet between the clusters defined by the first branch point of the clustering dendrogram
(p = 0.048), and also among the four different clusters defined by the second branch points (p < 0.0001). Analysis
also revealed differences in PrMet between the leiomyosarcomas (LMS), dedifferentiated liposarcomas (LipoD), and
undifferentiated pleomorphic sarcomas (UPS) (p = 0.0004). HC of both the LipoD and UPS sample sets divided the
samples into two groups with different PrMet (p = 0.0128, and 0.0002, respectively). HC of the UPS samples also
showed four groups with different PrMet (p = 0.0007). HC found no subgroups of the LMS samples.
Conclusions: These data confirm our earlier studies, and suggest that this approach may allow the identification of
more than two subsets of STS, each with distinct clinical behavior, and may be useful to stratify STS in clinical trials
and in patient management.
Keywords: Microarray, Sarcoma, Gene expression, Heterogeneity, Subgroups, Metastasis, PrognosisBackground
Soft tissue sarcomas (STS) represent a diverse group of
malignancies with different clinical behaviors. Adult STS
can be grouped into two broad categories. One category
has simple genomic profiles and specific cytogenetic
changes, such as a point mutation or translocation (for
example SYT-SSX in synovial sarcoma). The second cat-
egory is comprised of tumors with more complex genomic* Correspondence: skubi001@umn.edu
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unless otherwise stated.patterns characterized by multiple gains and losses, in-
cluding many leiomyosarcomas (LMS), pleomorphic lipo-
sarcomas, and undifferentiated pleomorphic sarcomas
(UPS) (previously termed malignant fibrous histiocyto-
mas) [1-5]. Although UPS may represent a distinct tumor
entity, many UPS have mRNA expression profiles that
are similar to other well defined subtypes of STS, in-
cluding LMS and liposarcoma, although they are not
easily recognized as such based on histology (http://
www.iarc.fr/en/publications/pdfs-online/pat-gen/bb5/bb5-
classifsofttissue.pdf) [6-10].
While some differences in behavior generally correlate
with histologic diagnosis and grade, significant heterogen-
eity of tumor biology exists even within histologic subsets.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ical care of patients with STS. One clinically important
variable is whether a tumor will metastasize or not.
Gene expression patterns may be useful in the subclas-
sification of STS, both for diagnosis and for prediction
of clinical behavior [2,7-16]. In some cases, gene expres-
sion patterns may correlate better with biological behav-
ior than histology, and some studies have suggested that
gene expression patterns may correlate with metastatic
potential in some high-grade STS [11,12,14,17]. A recent
study identified a set of 67 genes involved in mitosis and
chromosome integrity, termed the complexity index in
sarcomas (CINSARC), that can predict metastasis out-
come in non-translocation dependent STS [11] and also
synovial sarcoma [18].
In earlier studies, we described gene expression pro-
files that identified two general subgroups in a set of
clear cell renal cell carcinomas (ccRCC-gene set), a set
of ovarian carcinomas (OVCA-gene set), and a set of ag-
gressive fibromatosis samples (AF-gene set) [19-22]. We
recently reported the use of a gene set derived from
these three studies to separate 73 high grade STS into 2
or 4 groups with different propensity of metastasis [14].
Because the expression data for the STS sample set was
limited since it was from a different platform than the
Affymetrix system, we pooled the ccRCC-, OVCA-, and
AF-gene sets for the earlier study.
In this study we confirmed the results from our earlier
studies with an independent data set. We utilized our
three gene sets to examine a larger group of 309 non-
translocation associated STS using Affymetrix chip
based expression profiling, in data sets in which all
probes utilized in our earlier studies were represented.
These gene sets successfully separated the STS samples
into subsets with different probabilities of developing
metastases.Methods
Samples
Three hundred nine STS samples were obtained from
patients who had surgical resection of STS as previously
described [11]. The samples were from the FSG data-
base, part of the Conticabase (www.conticabse.org), and
were treated in one of 11 centers. In each case, the path-
ology was reviewed by the pathologist subgroup and
classified according to the 2002 WHO classification. For
the current study, STS with no recurrent chromosomal
translocation were selected. According to French law at
the time of the study, experiments were performed in
agreement with the Bioethics Law 2004 800 and the
Ethics Charter from the National Institute of Cancer; all
subjects signed a non-opposition statement for research
use of their sample.cDNA microarrays
Total RNA was extracted from each frozen tumor sam-
ple, and analyzed on Human Genome U133 Plus 2.0
array (Affymetrix) as previously described [11].
Gene sets
Three different gene sets with limited overlap, that identi-
fied two general subgroups of a series of ccRCC samples
(ccRCC-gene set), two subgroups of AF (AF-gene set),
and distinguished borderline from invasive serous OVCA
(OVCA-gene set) have been previously described, includ-
ing 138, 161, and 173 known genes respectively [19,21,22].
For the current study, these three gene sets were pooled
resulting in a set of 533 probes.
Hierarchical clustering and fold-change analysis
The ccRCC-, AF-, and OVCA- gene sets were used indi-
vidually or combined, to cluster the 309 primary high-
grade STS samples. For clustering, genes were median
centered, normalized, and then clustered by complete
hierarchical clustering using uncentered correlation with
the Eisen clustering software and viewed using the Tree-
View software (http://rana.lbl.gov). The geometric means
of the expression intensities of the relevant gene frag-
ments were computed using Genedata Expressionist
(Genedata, Basel, Switzerland), and the ratio was re-
ported as the fold change (up or down). Confidence in-
tervals and p-values on the fold change were calculated
using a two-sided Welch modified two-sample t-test.
Differences were considered significant when p</=0.05.
Analysis of time to metastasis
For each data set, we used the Kaplan-Meier (K-M)
method to calculate the metastasis-free survival probabil-
ities, and the cumulative probabilities of metastasis (i.e.
one minus survival probabilities) at critical time points
(2, 3, 5, and 10 years). The p-values were calculated by
using the Wilcoxon-Gehan test for comparing different
groups. The Tukey-Kramer method was used to adjust for
multiple pair-wise comparisons when there were more
than two groups. P-values </=0.05 were considered statis-
tically significant. Analyses were performed in SAS® 9.3
(SAS Institute, Cary, NC).
Results
Analysis of all STS samples using the combined gene set
Hierarchical clustering of the 309 STS samples was first
performed with the set of 533 probes of the combined
gene set (ccRCC-gene set, OVCA-gene set, and AF-gene
set) (Figure 1 top). Kaplan-Meier analysis was performed
using the two sample sets defined by the first branch
point (Groups A and B). The time to the development of
metastasis was significantly different between the two
sample sets (p = 0.048), with the probability of not
Figure 1 Top: clustering of gene expression in the 309
high-grade STS samples using the Eisen clustering software
Cluster. The samples were clustered by complete-linkage hierarchical
clustering with uncentered correlation using the Eisen clustering
software Cluster and the 533 probes present in the pooled gene
set as described in the text. Groups A and B are defined by the first
branch point in the clustering. Groups 1–4 are defined by the second
branch points. Middle and bottom: Kaplan-Meier analysis of the time
to development of metastases of the two groups (groups A and B)
and four groups (groups 1–4), defined by the first and second break
points, respectively, of the hierarchical clustering. The time to development
of metastasis differed between groups A and B (p = 0.048), and
groups 1–4 (p < 0.0001) (see Additional file 1: Table S1).
Figure 2 Kaplan-Meier analysis of the time to development of
metastases of the four groups of LMS, LipoD, UPS, and OTH
samples. The time to development of metastasis differed between
the groups, p = 0.0004 (see Additional file 1: Table S1).
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vs. 0.55 for Group B (Figure 1 middle, Additional file 1:
Table S1A).
Kaplan-Meier analysis was also performed using the
four sample sets defined by the first and second branch
points in the hierarchical clustering analysis (Groups 1–
4 in Figure 1 bottom). The time to the development of
metastasis differed among the four groups (p < 0.0001),with the probability of remaining free of metastasis by
5 years being 0.15, 0.77, 0.40, and 0.61 for groups 1, 2, 3,
and 4, respectively (Figure 1 bottom, Additional file 1:
Table S1B). Group comparisons by the Tukey-Kramer
method revealed significant differences between groups
1 and 2 (p < 0.0001), 1 and 4 (p = 0.0237), 2 and 3 (p <
0.0001), and 2 and 4 (p = 0.0314).Analysis of histologic subtypes
In examining Figure 1 bottom, we noticed that leiomyo-
sarcoma (LMS) samples were preferentially enriched in
group 1, and questioned the impact of differential mix-
tures of histologic diagnoses to the observed results. We
therefore questioned whether there was a difference in
probability of metastasis between the LMS, dedifferen-
tiated liposarcoma (LipoD), undifferentiated pleomorphic
sarcomas (UPS), and other sarcoma samples (OTH)
(which include all other diagnoses as described in refer-
ence 11) in our sample set. Analysis revealed that LMS
had a higher incidence of metastasis than the other three
diagnostic groups (p = 0.0004) (Figure 2, Additional file 1:
Table S1C). Group comparisons by the Tukey-Kramer
method showed significant differences between LMS and
LipoD (p = 0.0004), OTH (p = 0.0016), and UPS (p =
0.0138).Analysis of histologic subtypes using the combined gene
set
We next performed hierarchical clustering of the four
individual histologic types of STS (LipoD, UPS, LMS,
and OTH). Hierarchical clustering of the 62 LipoD sam-
ples with the pooled probe set divided the samples into
two groups (A and B) with different probabilities of
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(p = 0.0128).
Hierarchical clustering of the 136 UPS samples with the
pooled probe set divided the samples into two groups (A
and B) with different probabilities of metastasis (Figure 3
middle, Additional file 1: Table S1E) (p = 0.0002). Analysis
as four groups (1–4) also revealed statistically significant
differences (p = 0.0007) (Figure 3 bottom, Additional
file 1: Table S1F), suggesting further heterogeneity in
this tumor subset. Group comparisons by the Tukey-
Kramer method revealed significant differences between
groups 1 and 3 (p = 0.0012), and between groups 2 and
3 (p = 0.0051), while the other group comparisons did
not reach statistical significance.
In contrast, when the 84 LMS samples were analyzed
in the same manner, analysis of the groups formed by
the first 2 or 4 clusters defined by the hierarchical clus-
tering found no statistically significant differences (not
shown). Similarly, no difference was observed when a
similar analysis was performed using the 27 miscellan-
eous samples in the OTH subgroup (not shown). Factors
possibly contributing to the inability to identify groups
with different outcomes in the LMS and OTH sets could
include the small number of samples in these two sub-
groups, and the relative mix of “low” and “high” meta-
static samples in these two sample sets.Figure 3 Kaplan-Meier analysis of the time to development of
metastases of the two groups of LipoD samples (groups A and B),
defined by the first break point of the hierarchical clustering with
the pooled probe set (top panel). The time to development of
metastasis differed between groups A and B, p = 0.0128. Analysis of the
time to development of metastases of the two groups (groups A and B)
(middle panel), and four groups (groups 1–4) of UPS samples (bottom
panel) defined by the first and second break points, respectively, of
the hierarchical clustering with the pooled probe set. The time to
development of metastasis differed between groups A and B,
p = 0.0002, and groups 1–4, p = 0.0007 (see Additional file 1: Table S1).Analysis of histologic subtypes using the individual RCC-,
OVCA-, and AF-gene sets
We also analyzed the STS samples with the individual
AF-, OVCA-, and RCC-probe sets. Analysis of the UPS
subset with the RCC-gene set identified differences in
time to metastasis when the UPS samples were analyzed
as two groups (p = 0.0002) or four groups (p < 0.0007)
(Figure 4, top row, Additional file 1: Table S1 G,H).
Group comparisons by the Tukey-Kramer method re-
vealed significant differences between groups 1 and 4
(p = 0.0159) and 2 and 4 (p = 0.0005) with a trend be-
tween 2 and 3 (p = 0.0971). Analysis of the UPS samples
with the AF-gene set revealed differences in time to me-
tastasis when analyzed as two groups (p = 0.0007) or
four groups (p = 0.008) (Figure 4, second row, Additional
file 1: Table S1 I,J). Group comparisons by the Tukey-
Kramer method revealed significant differences between
groups 1 and 3 (p = 0.0500), and 2 and 3 (p = 0.0422),
with a trend between groups 2 and 4 (p = 0.1196) and 1
and 4 (p = 0.1451). Analysis of the UPS samples with the
OVCA-gene set found differences in time to metastasis
when the samples were analyzed as two (p = 0.004), or five
subgroups (Figure 4, third row, Additional file 1: Table S1,
K,L) (p = 0.0009). Group comparisons by the Tukey-
Kramer method revealed significant differences between
groups 1 and 3 (p = 0.0303) and 2 and 3 (p = 0.0004).
Figure 4 Top panel: Kaplan-Meier analysis of the time to development of metastases of the two groups (groups A and B) and the four
groups (groups 1–4) of UPS samples, defined by the first and second break points of the hierarchical clustering with the RCC-gene set.
The time to development of metastasis differed between groups A and B, p = 0.0002 and groups 1–4, p < 0.0007 (see Additional file 1: Table S1).
Second row: Kaplan-Meier analysis of the time to development of metastases of the two (groups A and B) and four groups (groups 1–4) of UPS
samples defined by the first and second break points, respectively, of the hierarchical clustering with the AF-gene set. The time to development
of metastasis differed between groups A and B, p = 0.0007, and groups 1–4, p = 0.008 (see Additional file 1: Table S1). Third row: Kaplan-Meier
analysis of the time to development of metastases of the two groups (groups A and B), and five groups (groups 1–5) of the UPS samples, defined
by the first break point, and visual separation of the break points, respectively, of the hierarchical clustering with the OVCA-gene set. The time to
development of metastasis differed between groups A and B, p = 0.004, and between groups 1–5, p = 0.0009 (see Additional file 1: Table S1).
Bottom row: Kaplan-Meier analysis of the time to development of metastases of the four groups of LipoD samples defined by the second break
points of the hierarchical clustering with the AF-gene set, p = 0.011 (see Additional file 1: Table S1).
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samples and analyzed as two groups the difference in
time to metastasis did not reach statistical significance
(not shown). Although when analyzed as four subgroups,
statistically significant differences in time to metastasis
were observed (Figure 4 bottom, Additional file 1: TableS1 M) (p = 0.011). Group comparisons by the Tukey-
Kramer method revealed significant differences between
groups 2 and 4 (p = 0.0384) and 3 and 4 (p = 0.0220).
When either the RCC-gene set or the OVCA-gene set
was used to cluster the LipoD samples, no significant
difference in time to metastasis was noted when analyzed
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shown). None of the individual AF-, RCC-, or OVCA-
gene sets separated the LMS or OTH samples into groups
of different metastatic propensity.
Effect of tumor grade on probability of developing
metastases
Tumor grade is correlated with survival in STS, and we
therefore questioned whether this might contribute to
our observations. We performed Kaplan-Meier analyses
of the LipoD and UPS subgroups defined by clustering
with the total gene set as in Figure 3 top and middle,
but excluded the 7 LipoD and 7 UPS samples that were
histologically grade 1 tumors. In the case of the LipoD
samples, the samples present in the first two groups de-
fined by clustering still differed in the probability of de-
veloping metastases (p = 0.0545) (not shown). Similarly,
when the UPS samples were analyzed without grade 1
tumors, a difference in probability of metastasis was ob-
served when analyzed as two groups (p = 0.0004) or four
groups (p = 0.001) (not shown). Group comparisons
using the Tukey-Kramer method found significant differ-
ences between groups 1 and 3 (p = 0.002) and 2 and 3
(p = 0.006). Therefore, the subgroups identified by clus-
tering in Figure 3 were not accounted for by differences
in content of grade 1 tumors.
Effect of stage on probability of developing metastasis
Since clinical grade is correlated with survival in STS,
we questioned whether this might contribute to our ob-
servations. When the LipoD samples were analyzed by
AJC (American Joint Commission) stage, no significant
difference in the probability of developing metastases
was seen between stage III (n = 17) vs IIA (n = 2), III vs
IIB (n = 26), or IIA vs IIB, though the difference between
stage III and IIA trended toward significance at p = 0.15
by Tukey-Kramer, and the rank order was as expected.
When the UPS samples were analyzed by stage (IIA, n =
23; IIB, n = 30; III, n = 65), the three stages also did not
differ in risk of metastases, though the difference be-
tween stage IIA and III and that between stage IIB and
III also trended to significance, both at p = 0.07, and the
rank order was again as expected. The lack of good cor-
relation between stage and metastases seen here may re-
flect the limited number of cases examined in the
different stages, and the fact that most cases were either
IIA, IIB, or III.
Correlations between AJC stage and clustering
For the UPS samples, AJC stage was significantly corre-
lated with both the two groups and four groups defined
by clustering (Figure 3, middle and bottom) (p = 0.03
and 0.02, respectively). For the LipoD samples, AJC stagewas not significantly correlated with the two groups
formed by clustering (Figure 3, top).Differential gene expression between subgroups
We next examined the most differentially expressed
genes of the total detected in the Affymetrix U133 Plus
chip set, in the first two subsets (groups A and B) of
LipoD and UPS (Figure 3, top and middle). Fold change
analysis was performed as described in the Methods,
and the genes most over- or under-expressed between
the groups are shown for LipoD in Additional file 2:
Table S2 and for UPS in Additional file 3: Table S3.
When the global gene expression of the LipoD-A sub-
set was compared with the LipoD-B subset (Figure 3
top), many differences were found (Additional file 2:
Table S2). For example, in the LipoD-A subset (the better
prognosis group) several genes that would be expected to
be expressed in adipocytes, including: ADIPOQ, PLIN1,
FABP4, LPL, PPARG, and THRSP were over-expressed
compared with the LipoD-B subset, as well as ALDH1,
ADH1B, and NTRK2 (Additional file 2: Table S2A). This
may correlate with a less “de-differentiated” state. In con-
trast, genes over-expressed in the LipoD-B subset (the
worse prognosis group) compared to the LipoD-A subset
included: RUNX2, CDC20, TOP2A, ANLN, multiple
members of the kinesin family, CDK1, AURKA, CCNB1,
CDKN3, LOX, CKS2, CCNA2, PDPN, AURKB, CCNE2,
and the extracellular matrix genes FN1 and CTHRC1
(Additional file 2: Table S2B).
The most over-expressed gene in the UPS-A subset
(the good prognosis group) was SCARA5, scavenger re-
ceptor class A, member 5, a gene that may act as a tumor
suppressor in some models [23]. Other genes over-
expressed in UPS-A compared to UPS-B included: TNXB,
ALDH1A3, ADA1B, MFAP5, AKAP12, DEFB1, TGFBR3,
GAS7, IL17D, IL33, and CD34, as well as the growth fac-
tors NEGR1, PDGFD, FGF18, NTRK2, and IGFBP6, a
regulator of IGF1 (Additional file 3: Table S3A). In con-
trast, genes over-expressed in the UPS-B subset (the bad
prognosis group) compared with the UPS-A subset
included: STEAP1, CA12, AIM2, TNC, HS3ST3A1,
RUNX2, POSTN, ADAM12, PLAUR, NRP2, RGS1, extra-
cellular matrix proteins COL11A1, COL10A1, and FN,
matrix metalloproteinases MMP9, MME, MMP13, and
MMP1, FAP (a marker of fibroblast activation), and
growth regulator proteins (Additional file 3: Table S3B).
Several genes were upregulated in both UPS-B and
LipoD-B (the poor prognosis groups) relative to UPS-A
and LipoD-A, respectively (Additional file 4: Table S4).
Only one of these genes, RRM2, is present in the CIN-
SARC gene set [11]. Five of these genes, RRM2, LEF1,
KDELR3, FN1, and CTHRC1, were present in the RCC-
gene set; two genes, MICAL2 and KDELR3, were present
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the OVCA-gene set.
Discussion
In the current study, 309 cases of four histologic sub-
types (LipoD, UPS, LMS, OTH) of non-translocation as-
sociated soft tissue sarcoma (STS) were separated into
subsets with different probability of metastasis using
gene sets derived from our earlier studies with ccRCC,
AF, and OVCA [15,19-22]. Each of the three gene sets
separated the 136 UPS samples into two groups of dif-
fering metastatic propensity, while the AF-gene set also
identified four subsets of the 62 LipoD samples. These
data support the concept that these gene sets may pre-
dict biological behavior in some STS. The data also con-
firmed differences in the metastatic propensity between
LMS and the other STS examined.
Both the current and CINSARC gene sets identified
subsets of the UPS samples, when analyzed as a separate
group, that differed in time to metastasis. Interestingly,
the current study also detected subsets of LipoD, when
analyzed as a separate group, that differed in probability of
metastasis, but did not detect such subsets in the LMS or
OTH subgroups. These differences were apparent even
after excluding grade 1 tumors from the analysis. In con-
trast, the CINSARC gene set identified subsets of LMS,
when analyzed as a separate group, that differed in prob-
ability of metastasis, but did not detect such subsets in the
LipoD subgroup [11]. Copy number losses, which may
also reflect genomic instability, have recently been shown
to identify subgroups of LipoD with a poor prognosis [24].
These results are consistent with the hypothesis that gene
expression patterns that correlate with metastatic propen-
sity may depend on the background gene expression of
the tumor, which may be determined by other gene sets
and partly reflected by histology. For example, a set of
genes that predicts metastasis in LMS might not be pre-
dictive in UPS, or a gene might be predictive in lung can-
cer but not colon cancer.
Differences were observed in the global gene expres-
sion patterns of the subsets that were identified in this
study. For example, the subset of the LipoD samples
with the lower probability of metastasis (LipoD-A)
tended to over-express a number of genes expressed in
adipocytes such as ADIPOQ, PLIN1, FABP4, LPL,
PPARG, and THRSP. These samples might be viewed as
less de-differentiated. Adiponectin, encoded by the ADI-
POQ gene, is a hormone produced in adipose tissue that
regulates several metabolic processes including fatty acid
catabolism. It is strongly expressed in preadipocytes dif-
ferentiating to adipocytes [25,26]. Perilipin, also known
as lipid droplet-associated protein, is encoded by the
PLIN1 gene and coats lipid droplets in adipocytes, acting
as a coating that separates lipids from lipases. FABP4,also known as adipocyte protein 2, is a carrier protein
for fatty acids and is expressed in adipocytes and macro-
phages. Lipoprotein lipase (LPL) is expressed in a num-
ber of tissues; the form in adipocytes is activated by
insulin. PPARG, or peroxisome proliferator-activated re-
ceptor gamma, is a nuclear receptor that regulates fatty
acid storage and glucose metabolism. PPARG activates
genes that stimulate lipid uptake and adipogenesis by fat
cells. THRSP, or thyroid hormone responsive SPOT14,
plays an important role in regulating lipid metabolism
[27]. Interestingly, SPOT14 has been reported to be a
marker of aggressive breast cancer [28].
Other genes that were over-expressed in the LipoD-A
subset of samples included ALDH1, ADH1B, and
NTRK2. Alcohol dehydrogenase 1B (ADH1B) metabo-
lizes a variety of substrates. Aldehyde dehydrogenase 1
(ALDH1) oxidizes aldehydes to carboxylic acids and also
metabolizes a variety of substrates. ALDH1 is a member
of a superfamily of genes and has been reported to be a
marker of normal and malignant mammary stem cells,
and a predictor of poor clinical outcome in breast cancer
[29]. NTRK2 functions as a receptor for several neuro-
trophins, including BDNF, NT-3, and NT-4; it can medi-
ate several effects, including differentiation and survival.
In contrast, the LipoD-B subset (with the higher risk
of developing metastatic disease) over-expressed a num-
ber of genes involved in regulating cell growth and cell
division. Among the genes over-expressed in the LipoD-
B subset compared to the LipoD-A subset, RUNX2 is a
transcription factor that has a Runt DNA-binding do-
main and is active in osteoblast differentiation. CDC20
(cell-division cycle protein 20), cyclin B1 (CCNB1), cyc-
lin A2 (CCNA2), cyclin E2 (CCNE2), cyclin-dependent
kinase-1 (CDK1, also known as CDC2), cyclin-dependent
kinases regulatory subunit 2 (CKS2), and cyclin-
dependent kinase inhibitor 3 (CDKN3), aurora A kin-
ase (AURKA), and aurora B kinase (AURKB) are
involved in regulating cell division. TOP2A (DNA
topoisomerase 2-alpha) is important in DNA replication
and is felt to be a target for doxorubicin and etoposide. In
some models, higher levels of TOP2A correlated with
more resistance to doxorubicin [30]. Podoplanin (PDPN)
is a mucin-like protein expressed in a variety of cells. Not-
ably, PDPN is a specific marker for lymphatic endothelial
cells, and has been shown to be over-expressed in a variety
of tumors. ANLN (actin binding protein anillin) binds
actin, but is also localized to the nucleus in some cancer
cells, and has been reported to be over-expressed in hor-
mone resistant prostate cancer and squamous cell head
and neck cancer. Lysyl oxidase (LOX) is a copper contain-
ing enzyme that catalyzes the formation of aldehydes from
lysine, especially in collagen and elastin [31]. LOX is regu-
lated by hypoxia-inducible factors (HIFs) and has been re-
ported to be upregulated in a number of cancers. In a
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and such inhibitors could eventually be clinically useful
[33]. Many of these regulatory proteins could serve as
drug targets.
Extracellular matrix genes were also differentially
expressed in the two LipoD subsets, with FN1 and
CTHRC1 over-expressed in LipoD-B. Differential ex-
pression of extracellular matrix proteins in different
subsets of malignancies appears to be a common theme.
The recognition of a desmoplastic response to cancer
has long been recognized [34-36], and tumor-associated
fibroblasts may play a role in cancer growth and devel-
opment [37-42]. The expression of several extracellular
matrix and collagen genes has been related to invasion
and survival in other tumors [43-45], and studies in
breast cancer described two types of stromal responses:
a fibromatosis-like stromal gene signature and a CSF-1
macrophage stromal gene signature [46].
Genes over-expressed in UPS-A (the good prognosis
group) compared to UPS-B included: SCARA5, TNXB,
ALDH1A3, ADH1B, MFAP5, AKAP12, DEFB1, TGFBR3,
GAS7, IL17D, IL33, and CD34, as well as the growth fac-
tors NEGR1, PDGFD, FGF18, NTRK2, and IGFBP6, a
regulator of IGF1. SCARA5 was expressed 34-fold higher
in the UPS-A subgroup, and may function as a tumor
suppressor gene. Over-expression of SCARA5 sup-
pressed some malignant behaviors in hepatoma cells,
and SCARA5 knockdown was associated with activation
of MMP9 [23]. Tenascin-XB (TNXB) is an extracellular
matrix protein that may regulate collagen deposition by
fibroblasts. Immune related proteins over expressed in
UPS-A included: DEFB1 (defensin beta 1), IL17D, IL33,
and A-kinase anchor protein 12 (AKAP12).
In contrast, genes over-expressed in UPS-B (the bad
prognosis group) compared to UPS-A (the good prog-
nosis group) included: STEAP1, CA12, AIM2, TNC,
HS3ST3A1, RUNX2, POSTN, ADAM12, PLAUR, NRP2,
RGS1, extracellular matrix proteins (COL11A1, COL10A1,
FN), matrix metalloproteinases (MMP9, MME, MMP13,
MMP1), FAP (a marker of fibroblast activation), and
growth regulator proteins. Six-transmembrane epithelial
antigen of the prostate (STEAP1) is an antigen detected
in prostate cells, but up-regulated in multiple cancer
cell lines, and is a metalloreductase. Recent studies on
the expression patterns of STEAP1 and STEAP2 have
suggested that they may be markers of mesenchymal
stem cells [47]. High STEAP1 expression in Ewing sar-
coma has been reported to be associated with an im-
proved outcome [48]. In contrast, STEAP1 expression
has also been reported to promote invasiveness in
Ewing tumors [49]. PLAUR has been associated with
cell migration, cell adhesion, and cell cycle regulation.
Of the genes upregulated in both of the poor-
prognosis groups (UPS-B and LipoD-B) compared withUPS-A and LipoD-A, respectively, only RRM2 is present
in the CINSARC gene set; five genes, RRM2, LEF1,
KDELR3, FN1, and CTHRC1, were present in the RCC-
gene set; two genes, MICAL2 and KDELR3, were present
in the AF-gene set; and one gene, RRM2, was present
in the OVCA-gene set. The RRM2 gene encodes
ribonucleoside-diphosphate reductase subunit M2, one
of two subunits for ribonucleotide reductase. Ribonucle-
otide reductase catalyzes the formation of deoxyribonu-
cleotides from ribonucleotides, a rate-limiting step in
DNA synthesis, and is regulated in a cell-cycle dependent
manner. Over-expression of RRM2 has been reported to
enhance the metastatic potential of some tumors [50].
LEF1 is a transcription factor involved in the Wnt-
signaling pathway, and has been associated with other
malignancies. KDELR3 is a receptor involved in protein
sorting in the endoplasmic reticulum. MICAL2 is a
monooxygenase that promotes depolymerization of F-
actin, and has also been associated with progression of
prostate cancer.
Although in the current study we focused on the iden-
tification of at most four subsets of each STS set with
different biological behavior (manifest as metastatic pro-
pensity), in some cases we observed statistically signifi-
cant differences in time to metastasis when the samples
were analyzed as more than four subsets. The ability to
detect multiple subgroups is strongly influenced by sam-
ple number and the distribution of samples among the
various groups. Perhaps further heterogeneity that is
clinically useful may be identified in larger sample sets.
The ability to better predict the long-term outcome fol-
lowing surgery will greatly improve the treatment of pa-
tients with sarcomas, and gene expression profiles may
provide a clinically meaningful approach to this prob-
lem, restricting the use of adjuvant modalities of therapy
and reducing heterogeneity among groups in clinical tri-
als of new drugs.
Conclusions
The biologic heterogeneity of soft tissue sarcomas (STS),
even within histological subtypes, complicates treatment.
This study used hierarchical clustering with a gene set
derived from studies of renal carcinoma, ovarian carcin-
oma, and aggressive fibromatosis, to examine 309 STS
using Affymetrix chip expression profiling. The analysis
separated STS into two groups, and also four groups,
with different probabilities of developing metastatic
disease (PrMet). Analysis also revealed differences in
PrMet between leiomyosarcomas (LMS), dedifferentiated-
liposarcomas (LipoD), and undifferentiated pleomorphic
sarcomas (UPS). HC of both the LipoD and UPS samples
divided the samples into two groups with different PrMet.
HC of the UPS samples also showed four groups with dif-
ferent PrMet. These data confirm our earlier studies in
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http://www.translational-medicine.com/content/12/1/176with a different sample set, and suggest that this ap-
proach may allow the identification of more than two
subsets of STS, each with distinct clinical behavior, and
may be useful to stratify STS in clinical trials and in pa-
tient management.
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